Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Vaccine ; 37(2): 333-342, 2019 01 07.
Article in English | MEDLINE | ID: mdl-30522906

ABSTRACT

A human cytomegalovirus (HCMV) vaccine to prevent infection and/or reduce disease associated with congenital infection or visceral disease in transplant recipients is a high priority, but has remained elusive. We created a disabled infectious single cycle rhesus CMV (RhCMV) deleted for glycoprotein L (gL) and the MHC class I immune evasion genes Rh178 and Rh182-189, and restored its epithelial cell tropism by inserting the Rh128-131A genes. The resulting virus, RhCMVRΔgL/178/182-189, was used to vaccinate rhesus monkeys intramuscularly and was compared with vaccination of animals with soluble RhCMV glycoprotein B (gB) in alum/monophosphoryl lipid A or with PBS as a control. At 4 weeks after the second vaccination, an increased frequency of RhCMV-specific CD8 T cells was detected in animals vaccinated with the RhCMVRΔgL/178/182-189 vaccine compared to animals vaccinated with soluble gB. In contrast, monkeys vaccinated with soluble gB had 20-fold higher gB antibody titers than animals vaccinated with RhCMVRΔgL/178/182-189. Titers of neutralizing antibody to RhCMV infection of fibroblasts were higher in animals vaccinated with gB compared with RhCMVRΔgL/178/182-189. Following vaccination, monkeys were challenged subcutaneously with RhCMV UCD59, a low passage virus propagated in monkey kidney epithelial cells. All animals became infected after challenge; however, the frequency of RhCMV detection in the blood was reduced in monkeys vaccinated with soluble gB compared with those vaccinated with RhCMVRΔgL/178/182-189. The frequency of challenge virus shedding in the urine and saliva and the RhCMV copy number shed at these sites was not different in animals vaccinated with RhCMVRΔgL/178/182-189 or soluble gB compared with those that received PBS before challenge. Although the RhCMVRΔgL/178/182-189 vaccine was superior in inducing cellular immunity to RhCMV, it induced lower titers of neutralizing antibody and antibody to gB than the soluble gB vaccine; after challenge, animals vaccinated with soluble gB had a lower frequency of virus detection in the blood than those vaccinated with RhCMVRΔgL/178/182-189.


Subject(s)
Cytomegalovirus Infections/prevention & control , Cytomegalovirus/immunology , Defective Viruses/immunology , Gene Deletion , Genes, MHC Class I , Immune Evasion/genetics , Animals , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Cytomegalovirus/physiology , Cytomegalovirus Infections/immunology , DNA, Viral/blood , Defective Viruses/genetics , Macaca mulatta , Vaccination/methods , Viral Envelope Proteins/genetics , Virus Replication
2.
Clin Dev Immunol ; 2013: 906948, 2013.
Article in English | MEDLINE | ID: mdl-24000289

ABSTRACT

Development of a vaccine against congenital cytomegalovirus (CMV) infection is a public health priority, but CMVs encode immune evasion genes that complicate live virus vaccine design. To resolve this problem, this study employed guanosyl phosphoribosyl transferase (gpt) mutagenesis to generate a recombinant guinea pig CMV (GPCMV) with a knockout of a viral chemokine gene, GPCMV MIP (gp1). MIP deletion virus replicated with wild-type kinetics in cell culture but was attenuated in nonpregnant guinea pigs, demonstrating reduced viremia and reduced inflammation and histopathology (compared to a control virus with an intact GPCMV MIP gene) following footpad inoculation. In spite of attenuation, the vaccine was immunogenic, eliciting antibody responses comparable to those observed in natural infection. To assess its protective potential as a vaccine, either recombinant virus or placebo was used to immunize seronegative female guinea pigs. Dams were challenged in the early 3rd trimester with salivary gland-adapted GPCMV. Immunization protected against DNAemia (1/15 in vaccine group versus 12/13 in the control group, P < 0.01). Mean birth weights were significantly higher in pups born to vaccinated dams compared to controls (98.7 g versus 71.2 g, P < 0.01). Vaccination reduced pup mortality, from 35/50 (70%) in controls to 8/52 (15%) in the immunization group. Congenital GPCMV infection was also reduced, from 35/50 (70%) in controls to 9/52 (17%) in the vaccine group (P < 0.0001). We conclude that deletion of an immune modulation gene can attenuate the pathogenicity of GPCMV while resulting in a viral vaccine that retains immunogenicity and demonstrates efficacy against congenital infection and disease.


Subject(s)
Cytomegalovirus Infections/prevention & control , Cytomegalovirus Infections/transmission , Cytomegalovirus Vaccines/immunology , Cytomegalovirus/genetics , Cytomegalovirus/immunology , Infectious Disease Transmission, Vertical , Vaccines, Attenuated/immunology , Viral Proteins/genetics , Animals , Cell Line , Cytomegalovirus Vaccines/administration & dosage , Cytomegalovirus Vaccines/adverse effects , Female , Gene Order , Guinea Pigs , Pregnancy , Pregnancy Outcome , Sequence Deletion , Vaccination , Vaccines, Attenuated/administration & dosage , Vaccines, Attenuated/adverse effects , Virus Replication
3.
J Virol ; 85(5): 2089-99, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21191007

ABSTRACT

Rhesus cytomegalovirus (RhCMV), the homolog of human cytomegalovirus (HCMV), serves as a model for understanding the pathogenesis of HCMV and for developing candidate vaccines. In order to develop a replication-defective virus as a vaccine candidate, we constructed RhCMV with glycoprotein L (gL) deleted. RhCMV gL was essential for viral replication, and virus with gL deleted could only replicate in cells expressing RhCMV gL. Noncomplementing cells infected with RhCMV with gL deleted released intact, noninfectious RhCMV particles that were indistinguishable from wild-type RhCMV by electron microscopy and could be rescued by treatment of cells with polyethylene glycol. In addition, noncomplementing cells infected with RhCMV with gL deleted produced levels of gB, the major target of neutralizing antibodies, at levels similar to those observed in cells infected with wild-type RhCMV. Since RhCMV and HCMV gL share 53% amino acid identity, we determined whether the two proteins could complement the heterologous virus. Cells transfected with an HCMV bacterial artificial chromosome with gL deleted yielded virus that could replicate in human cells expressing HCMV gL. This is the second HCMV mutant with an essential glycoprotein deleted that has been complemented in cell culture. Finally, we found that HCMV gL could not complement the replication of RhCMV with gL deleted and that RhCMV gL could not complement the replication of HCMV with gL deleted. These data indicate that RhCMV and HCMV gL are both essential for replication of their corresponding viruses and, although the two gLs are highly homologous, they are unable to complement each another.


Subject(s)
Cytomegalovirus Infections/veterinary , Cytomegalovirus Infections/virology , Cytomegalovirus/physiology , Primate Diseases/virology , Viral Proteins/metabolism , Animals , Cell Line , Cytomegalovirus/genetics , Cytomegalovirus/pathogenicity , Humans , Macaca mulatta , Viral Envelope Proteins , Viral Proteins/genetics , Virulence , Virus Replication
4.
J Clin Neurophysiol ; 27(3): 191-2, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20461015

ABSTRACT

The objective of this study is to determine the yield of routine outpatient electroencephalogram (EEG) in the diagnosis of epilepsy in the veteran population. All consecutive outpatient EEGs at the James A. Haley Veterans Affairs Hospital in Tampa, FL from October 31, 2005, to October 30, 2007, were retrospectively reviewed. During the 2 years of the study, 636 routine outpatient EEGs were performed at James A. Haley Veterans Affairs Hospital. The age range for the patients was 21 to 97 years with a mean age of 55 years. Eighty-five EEGs (13.4%) were classified as abnormal. Nineteen EEGs (3%) in the past 2 years contained epileptiform abnormalities. Sixty-eight EEGs (10.7%) had other abnormalities such as slowing, asymmetry, excessive beta activity, or a combination of abnormalities. Thirty-six EEGs (5.7%) clearly demonstrated psychogenic nonepileptic attacks as documented by normal EEG and video recording of the patient's habitual event. Single routine outpatient EEG has been reported to have a sensitivity of 29% to 55% in detecting interictal epileptiform discharges in patients with a suspected diagnosis of epilepsy. In our study, only about 3% of the patients had clear abnormalities suggestive of epilepsy. Interestingly, by using routine EEGs, we were able to definitively diagnose more patients with psychogenic nonepileptic attacks than epileptic seizures.


Subject(s)
Electroencephalography , Epilepsy/diagnosis , Veterans , Adult , Aged , Aged, 80 and over , Epilepsy/physiopathology , Follow-Up Studies , Hospitals, Veterans , Humans , Middle Aged , Outpatients , Retrospective Studies
5.
J Infect Dis ; 195(6): 789-98, 2007 Mar 15.
Article in English | MEDLINE | ID: mdl-17299708

ABSTRACT

Development of a vaccine against congenital cytomegalovirus (CMV) infection is a major public health priority. We report the use of a propagation-defective, single-cycle, RNA replicon vector system, derived from an attenuated strain of the alphavirus Venezuelan equine encephalitis virus, to produce virus-like replicon particles (VRPs) expressing GP83, the guinea pig CMV (GPCMV) homolog of the human CMV pp65 phosphoprotein. Vaccination with VRP-GP83 induced antibodies and CD4(+) and CD8(+) T cell responses in GPCMV-seronegative female guinea pigs. Guinea pigs immunized with VRP-GP83 vaccine or with a VRP vaccine expressing influenza hemagglutinin (VRP-HA) were bred for pregnancy and subsequent GPCMV challenge during the early third trimester. Dams vaccinated with VRP-GP83 had improved pregnancy outcomes, compared with dams vaccinated with the VRP-HA control. For VRP-GP83-vaccinated dams, there were 28 live pups and 4 dead pups (13% mortality) among 10 evaluable litters, compared with 9 live pups and 12 dead pups (57% mortality) among 8 evaluable litters in the VRP-HA-vaccinated group (P<.001, Fisher's exact test). Improved pregnancy outcome was accompanied by reductions in maternal blood viral load, measured by real-time polymerase chain reaction. These results indicate that cell-mediated immune responses directed against a CMV matrix protein can protect against congenital CMV infection and disease.


Subject(s)
Cytomegalovirus/immunology , Immunity, Cellular , Phosphoproteins/immunology , Viral Matrix Proteins/immunology , Viral Vaccines/therapeutic use , Animals , Animals, Newborn , Base Sequence , DNA Primers , Disease Models, Animal , Female , Guinea Pigs , Humans , Infant, Newborn , Molecular Sequence Data , Pregnancy , Pregnancy Outcome , Replicon/immunology , Salivary Glands/virology , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL
...